BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36230824)

  • 1. Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study.
    Heestermans R; De Brouwer W; Maes K; Vande Broek I; Vaeyens F; Olsen C; Caljon B; De Becker A; Bakkus M; Schots R; Van Riet I
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities.
    Heestermans R; Schots R; De Becker A; Van Riet I
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
    Kis O; Kaedbey R; Chow S; Danesh A; Dowar M; Li T; Li Z; Liu J; Mansour M; Masih-Khan E; Zhang T; Bratman SV; Oza AM; Kamel-Reid S; Trudel S; Pugh TJ
    Nat Commun; 2017 May; 8():15086. PubMed ID: 28492226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.
    Garcés JJ; Bretones G; Burgos L; Valdes-Mas R; Puig N; Cedena MT; Alignani D; Rodriguez I; Puente DÁ; Álvarez MG; Goicoechea I; Rodriguez S; Calasanz MJ; Agirre X; Flores-Montero J; Sanoja-Flores L; Rodriguez-Otero P; Rios R; Martinez-Lopez J; Millacoy P; Palomera L; Del Orbe R; Pérez-Montaña A; El Omri H; Prosper F; Mateos MV; Rosiñol L; Blade J; Lahuerta JJ; Orfao A; Lopez-Otin C; San Miguel JF; Paiva B;
    Leukemia; 2020 Nov; 34(11):3007-3018. PubMed ID: 32475991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.
    Keup C; Storbeck M; Hauch S; Hahn P; Sprenger-Haussels M; Tewes M; Mach P; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30781720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer.
    Thakur K; Singh MS; Feldstein-Davydova S; Hannes V; Hershkovitz D; Tsuriel S
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Immunoglobulin Gene Rearrangement Biomarkers in Multiple Myeloma through cfDNA-Based Liquid Biopsy Using tchDNA-Seq.
    Buenache N; Sánchez-delaCruz A; Cuenca I; Giménez A; Moreno L; Martínez-López J; Rosa-Rosa JM
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
    BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
    Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
    BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma.
    Reale A; Khong T; Xu R; Chen M; Mithraprabhu S; Bingham N; Spencer A; Greening DW
    Methods Mol Biol; 2021; 2261():151-191. PubMed ID: 33420989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
    Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
    Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients.
    Keup C; Storbeck M; Hauch S; Hahn P; Sprenger-Haussels M; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32349306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer.
    Keup C; Suryaprakash V; Hauch S; Storbeck M; Hahn P; Sprenger-Haussels M; Kolberg HC; Tewes M; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Genome Med; 2021 May; 13(1):85. PubMed ID: 34001236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers.
    Strauss WM; Carter C; Simmons J; Klem E; Goodman N; Vahidi B; Romero J; Masterman-Smith M; O'Regan R; Gogineni K; Schwartzberg L; Austin LK; Dempsey PW; Cristofanilli M
    Oncotarget; 2016 May; 7(18):26724-38. PubMed ID: 27049831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.
    Daniel M; Knutson TP; Sperger JM; Li Y; Singh A; Stahlfeld CN; Passow C; Auch B; Lang JM; Dehm SM
    Endocr Relat Cancer; 2021 Aug; 28(9):645-655. PubMed ID: 34280123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
    Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
    Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study.
    Ferreira BV; Carneiro EA; Pestana C; Barahona F; Caetano J; Lopes R; Lúcio P; Neves M; Beck HC; Carvalho AS; Matthiesen R; Costa-Silva B; João C
    Front Oncol; 2022; 12():860849. PubMed ID: 35800053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.